INDP: Indaptus Therapeutics, Inc. Stock

by  •  • Comments Off on INDP: Indaptus Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 13.04
Enterprise Value ($M) 5.66
Book Value ($M) 6.00
Book Value / Share 0.43
Price / Book 2.17
NCAV ($M) 5.39
NCAV / Share 0.38
Price / NCAV 2.42

Profitability (mra)
Return on Invested Capital (ROIC) -2.44
Return on Assets (ROA) -1.00
Return on Equity (ROE) -1.23

Liquidity (mrq)
Quick Ratio 3.42
Current Ratio 3.42

Balance Sheet (mrq) ($M)
Current Assets 7.63
Assets 8.24
Liabilities 2.24
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-26 13D/A Meckler Jeffrey A 6.90 10.76

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 280 2,997 9.34
2025-02-03 2,389 15,889 15.04
2025-01-31 6,577 14,135 46.53
2025-01-30 4,068 22,995 17.69

(click for more detail)

Similar Companies
IMNM – Immunome, Inc. IMNN – Imunon, Inc.
IMTX – Immatics N.V. INKT – MiNK Therapeutics, Inc.
INM – InMed Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io